Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

Apr 17, 2023

SELL
$65.71 - $74.53 $57,693 - $65,437
-878 Reduced 21.97%
3,119 $216,000
Q4 2022

Jan 13, 2023

SELL
$68.48 - $81.09 $66,014 - $78,170
-964 Reduced 19.43%
3,997 $0
Q3 2022

Oct 20, 2022

SELL
$0.13 - $76.84 $1,266 - $748,575
-9,742 Reduced 66.26%
4,961 $352,000
Q2 2022

Jul 12, 2022

SELL
$72.62 - $79.98 $1.12 Million - $1.23 Million
-15,372 Reduced 51.11%
14,703 $1.13 Million
Q1 2022

Apr 21, 2022

BUY
$61.48 - $73.72 $96,400 - $115,592
1,568 Added 5.5%
30,075 $2.2 Million
Q4 2021

Feb 11, 2022

BUY
$53.63 - $62.52 $171,079 - $199,438
3,190 Added 12.6%
28,507 $1.78 Million
Q3 2021

Nov 15, 2021

BUY
$59.17 - $69.31 $10,591 - $12,406
179 Added 0.71%
25,317 $1.5 Million
Q2 2021

Aug 16, 2021

BUY
$61.91 - $67.42 $169,695 - $184,798
2,741 Added 12.24%
25,138 $1.68 Million
Q1 2021

May 17, 2021

BUY
$59.34 - $66.74 $1.12 Million - $1.26 Million
18,943 Added 548.44%
22,397 $1.41 Million
Q4 2020

Jan 29, 2021

BUY
$57.74 - $65.43 $199,433 - $225,995
3,454 New
3,454 $214,000
Q4 2017

Feb 26, 2018

SELL
$59.94 - $65.35 $439,540 - $479,211
-7,333 Closed
0 $0
Q3 2017

Nov 15, 2017

BUY
$55.23 - $63.74 $405,001 - $467,405
7,333
7,333 $467,000

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $113B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track First Heartland Consultants, Inc. Portfolio

Follow First Heartland Consultants, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of First Heartland Consultants, Inc., based on Form 13F filings with the SEC.

News

Stay updated on First Heartland Consultants, Inc. with notifications on news.